88 related articles for article (PubMed ID: 16982734)
1. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene.
Schmidt H; DeAngelis G; Eltze E; Gockel I; Semjonow A; Brandt B
Cancer Res; 2006 Sep; 66(18):8959-65. PubMed ID: 16982734
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
[TBL] [Abstract][Full Text] [Related]
3. [Early loss of heterozygosity on chromosome arm 16q in flat epithelial atypia of the breast. Detection by microsatellite analyses].
Schmidt H; Dahrenmöller C; Agelepoulos K; Hungermann D; Böcker W
Pathologe; 2008 Nov; 29 Suppl 2():328-32. PubMed ID: 18807038
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
[TBL] [Abstract][Full Text] [Related]
5. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
Fizazi K; Morat L; Chauveinc L; Prapotnich D; De Crevoisier R; Escudier B; Cathelineau X; Rozet F; Vallancien G; Sabatier L; Soria JC
Ann Oncol; 2007 Mar; 18(3):518-21. PubMed ID: 17322541
[TBL] [Abstract][Full Text] [Related]
6. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
7. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.
Schwarzenbach H; Alix-Panabières C; Müller I; Letang N; Vendrell JP; Rebillard X; Pantel K
Clin Cancer Res; 2009 Feb; 15(3):1032-8. PubMed ID: 19188176
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
9. PTEN/MMAC1/TEP1 involvement in primary prostate cancers.
Pesche S; Latil A; Muzeau F; Cussenot O; Fournier G; Longy M; Eng C; Lidereau R
Oncogene; 1998 Jun; 16(22):2879-83. PubMed ID: 9671408
[TBL] [Abstract][Full Text] [Related]
10. [Research on the mechanisms of PTEN gene inactivation in ovarian cancer].
Lü QJ; Zhao XD; Song JY; Li XH; Ma Y; Meng H; Jiang WG
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):266-9. PubMed ID: 16181546
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Aragon-Ching JB; Siegel RS; Frazier H; Andrawis R; Hendricks F; Phillips M; Jarrett T; Guebre-Xabiher H; Patierno S; Simmens SJ
Clin Genitourin Cancer; 2015 Oct; 13(5):e341-5. PubMed ID: 25956468
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of loss of heterozygosity on chromosome 10 in human prostate carcinoma and high grade prostatic intraepithelial neoplasia].
Wang ZM; Lai FM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct; 21(5):515-7. PubMed ID: 15476185
[TBL] [Abstract][Full Text] [Related]
13. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.
Markou A; Lazaridou M; Paraskevopoulos P; Chen S; Świerczewska M; Budna J; Kuske A; Gorges TM; Joosse SA; Kroneis T; Zabel M; Sedlmayr P; Alix-Panabières C; Pantel K; Lianidou ES
Clin Chem; 2018 Feb; 64(2):297-306. PubMed ID: 29122836
[TBL] [Abstract][Full Text] [Related]
14. Sample-to-Answer Isolation and mRNA Profiling of Circulating Tumor Cells.
Mohamadi RM; Ivanov I; Stojcic J; Nam RK; Sargent EH; Kelley SO
Anal Chem; 2015 Jun; 87(12):6258-64. PubMed ID: 26009151
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity of surgically resected prostate carcinomas and their biopsy specimens is related to their histologic differentiation.
Takimoto Y; Shimazui T; Akaza H; Sato N; Noguchi M
Cancer; 2001 Jan; 91(2):362-70. PubMed ID: 11180083
[TBL] [Abstract][Full Text] [Related]
16. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
[TBL] [Abstract][Full Text] [Related]
17. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.
Valeri A; Fromont G; Sakr W; Azzouzi R; Dey J; Chantrel-Groussard K; Latil A; Berthon P; Cussenot O; Pontes JE; Cher ML
Urol Oncol; 2005; 23(2):87-92. PubMed ID: 15869992
[TBL] [Abstract][Full Text] [Related]
18. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
19. Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
Feilotter HE; Nagai MA; Boag AH; Eng C; Mulligan LM
Oncogene; 1998 Apr; 16(13):1743-8. PubMed ID: 9582022
[TBL] [Abstract][Full Text] [Related]
20. Infrequent genetic alterations of the PTEN gene in Japanese patients with sporadic prostate cancer.
Orikasa K; Fukushige S; Hoshi S; Orikasa S; Kondo K; Miyoshi Y; Kubota Y; Horii A
J Hum Genet; 1998; 43(4):228-30. PubMed ID: 9852672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
